pirfenidone has been researched along with Graft vs Host Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brondstetter, T; Chatterjee, P; Cheng, GS; Chiu, W; Hsu, JL; Johnston, L; Matthaiou, EI; Morris, K; O'Donnell, C; Owyang, C; Sharifi, H; Turk, I | 1 |
| Alexander, KA; Antin, JH; Blazar, BR; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Lineburg, KE; Loschi, M; Luznik, L; MacDonald, KP; Maillard, I; Meng, J; Miklos, D; Panoskaltsis-Mortari, A; Paz, K; Ritz, J; Robinson, TM; Roy, S; Schacker, TW; Serody, JS; Vulic, A | 1 |
1 trial(s) available for pirfenidone and Graft vs Host Disease
| Article | Year |
|---|---|
The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.
Topics: Bronchiolitis Obliterans; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lung; Pyridones | 2022 |
1 other study(ies) available for pirfenidone and Graft vs Host Disease
| Article | Year |
|---|---|
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
Topics: Allografts; Animals; B-Lymphocytes; Bronchiolitis Obliterans; Chemokine CCL2; Disease Models, Animal; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Interleukin-17; Macrophages; Mice; Mice, Mutant Strains; Pulmonary Fibrosis; Pyridones; Skin Diseases; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta | 2017 |